 Epirubicin dose levels prednisolone treatment advanced breast cancer results randomized trial eleven patients advanced breast cancer epirubicin prednisolone LEP prednisolone HEP intended treatment courses LEP courses HEP intervals Reasons treatment progressive disease stable disease symptomatic improvement severe toxicity intolerable patient physician Toxicity response intervals World Health Organization WHO criteria response toxicity hundred patients eligible analysis year patients LEP HEP Significantly myelosuppression alopecia nausea vomiting mucositis high-dose arm equal patients LEP arm treatment fourth course HEP arm reason stopping progressive disease similar median number courses arm response HEP arm HEP complete response CR partial response PR LEP CR PR significant differences overall survival progression-free interval median survival HEP LEP weeks